From Aspect Huntley today:
Event
* The Board advises revenue target of $5-$7m for FY07 will not be met.
* Regulatory approval remains outstanding in Russia and Mexico. Due to a request for extended testing, Chinese approval decision will now be pushed back to Q3/Q4 CY07.
* The Board is undertaking a detailed assessment of sales activity and prospects for FY07, including the commissioning of an external review of the Company’s short and medium term strategic options.
Impact
* CEO, Bob Atwill recently told us the FY07 forecast was achievable. This recent announcement takes away all confidence in management.
* This adds doubt to all comments made by management on the demand from Clinicians for the ReCell product.
* The cash flow statements have so far failed to deliver and now question marks hover over demand for all of CCE’s products.
Recommendation Impact
(Last Updated: 20070219)
At this stage better opportunities appeal in other stocks, Sell
- Forums
- ASX - By Stock
- crunch time
From Aspect Huntley today:Event * The Board advises revenue...
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CCE (ASX) to my watchlist
|
|||||
Last
4.1¢ |
Change
-0.002(4.65%) |
Mkt cap ! $15.01M |
Open | High | Low | Value | Volume |
4.5¢ | 4.6¢ | 4.1¢ | $11.81K | 264.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 259347 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.5¢ | 15010 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 186132 | 0.041 |
8 | 846648 | 0.040 |
6 | 356294 | 0.039 |
8 | 585000 | 0.038 |
3 | 140883 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.045 | 15010 | 1 |
0.046 | 199782 | 1 |
0.047 | 21297 | 1 |
0.048 | 72000 | 2 |
0.049 | 270428 | 2 |
Last trade - 15.41pm 19/07/2024 (20 minute delay) ? |
Featured News
CCE (ASX) Chart |